We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Register to vote Register by 18 June to vote in the General Election on 4 July.
This study aims to identify the reasons for not undergoing confirmation by those at high risk for developing diabetes
The characteristics, diagnosis, management, surveillance and epidemiology of Pseudomonas aeruginosa.
Project Orbis is a programme to review and approve promising cancer drugs helping patients access treatments faster.
Chief Medical Officer for England, Professor Chris Whitty's annual reports and lectures on medicine and public health.
Volume 22 of the non-technical summaries granted under the Animals (Scientific Procedures) Act 1986 during 2013.
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (11 March 2024) approved the medicine quizartinib (Vanflyta) to be used alongside chemotherapy as first line treatment for adults who have acute myeloid leukaemia (AML).
Advice for medical professionals to follow when assessing drivers with diabetes mellitus.
Information explaining diabetic retinopathy, a disease screened for by the NHS diabetic eye screening (DES) programme.
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (6 March 2024) approved the medicine piflufolastat (18F) (Pylclari) as a diagnostic tool for people with suspected or known prostate cancer.
Quarterly updates to the emergency presentations of cancer data by Public Health England.
More people living with obesity will have access to the newest and most effective obesity drugs to help cut NHS waiting lists, following the announcement of a £40 million two-year pilot today [Wednesday 7 June].
How to use a cost effectiveness analysis to evaluate your digital health product.
You may need to tell DVLA if you have diabetes, depending on the treatment you're getting
Following MHRA approval of a clinical trial, early breast cancer patients on endocrine-based therapy can benefit from a study with camizestrant.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).